A Pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Tumban, Ebenezer ^a   Peabody, Julianne ^a   Peabody, David S ^a   Chackerian, Bryce ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN L1; CAPSID PROTEIN L2; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; WART VIRUS VACCINE; CAPSID PROTEIN; IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIOPHAGE; BACTERIOPHAGE PP7; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; CROSS REACTION; FEMALE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IN VIVO STUDY; INFECTION PREVENTION; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; SKIN INFECTION; UTERINE CERVIX CANCER; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; WART VIRUS; ALPHAPAPILLOMAVIRUS; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL STRAIN HEK293; COLIPHAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; IMMUNOLOGY; METHODOLOGY; MOLECULAR GENETICS; PEPTIDE LIBRARY; SEQUENCE HOMOLOGY; SERODIAGNOSIS; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; VIROLOGY;

HUMAN PAPILLOMAVIRUS; MIRIDAE; MUS;

ALPHAPAPILLOMAVIRUS; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HEK293 CELLS; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; LEVIVIRUS; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PEPTIDE LIBRARY; SEQUENCE HOMOLOGY, AMINO ACID; VACCINES, VIRUS-LIKE PARTICLE;

EID: 80051770278     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023310     Document Type: Article

References (40)

1. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, et al. (1991) Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J 60: 1445-1456.
2. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, et al. (2008) Arrangement of L2 within the papillomavirus capsid. J Virol 82: 5190-5197.
3. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC, (2000) Structure of Small Virus-like Particles Assembled from the L1 Protein of Human Papillomavirus 16. Molecular Cell 5: 557-567.
4. Doorbar J, Gallimore PH, (1987) Identification of proteins encoded by the L1 and L2 open reading frames of human papillomavirus 1a. J Virol 61: 2793-2799.
5. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H, (2004) Classification of papillomaviruses. Virology 324: 17-27.
6. Burd EM, (2003) Human papillomavirus and cervical cancer. Clin Microbiol Rev 16: 1-17.
7. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, et al. (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111: 278-285.
8. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199: 926-935.
9. Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, et al. (2007) Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 3: 109-115.
10. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 199: 936-944.
11. Schiller JT, Lowy DR, (2009) Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 200: 166-171.
12. Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, et al. (2008) Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A 105: 5850-5855.
13. Campo MS, Grindlay GJ, O'Neil BW, Chandrachud LM, McGarvie GM, et al. (1993) Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol.
14. Christensen ND, Kreider JW, Kan NC, DiAngelo SL, (1991) The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 181: 572-579.
15. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, et al. (2007) Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 81: 11585-11592.
16. Lin Y-L, Borenstein LA, Selvakumar R, Ahmed R, Wettstein FO, (1992) Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 187: 612-619.
17. Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT, (2008) Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol 82: 4638-4646.
18. Selinka HC, Giroglou T, Nowak T, Christensen ND, Sapp M, (2003) Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol 77: 12961-12967.
19. Richards RM, Lowy DR, Schiller JT, Day PM, (2006) Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A 103: 1522-1527.
20. Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, et al. (2010) In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 8: 260-270.
21. Campo MS, Roden RB, (2010) Papillomavirus prophylactic vaccines: established successes, new approaches. J Virol 84: 1214-1220.
22. Roden RB, Yutzy WI, Fallon R, Inglis S, Lowy DR, et al. (2000) Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270: 254-257.
23. Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, et al. (2005) Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337: 365-372.
24. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T, (1998) In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids. J Virol 72: 10298-10300.
25. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T, (1999) Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol 73: 6188-6190.
26. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, et al. (2007) A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 81: 13927-13931.
27. Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, et al. (2007) Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358: 266-272.
28. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, et al. (2009) Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 101: 782-792.
29. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT, (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89: 12180-12184.
30. Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, et al. (2007) A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 25: 2001-2010.
31. Schellenbacher C, Roden R, Kirnbauer R, (2009) Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol 83: 10085-10095.
32. Chackerian B, Durfee MR, Schiller JT, (2008) Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model. J Immunol 180: 5816-5825.
33. Caldeira Jdo C, Medford A, Kines RC, Lino CA, Schiller JT, et al. (2010) Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 28: 4384-4393.
34. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, et al. (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13: 857-861.
35. Bessa J, Kopf M, Bachmann MF, (2010) Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol 184: 4615-4619.
36. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, et al. (2011) Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470: 543-547.
37. Buck CB, Pastrana DV, Lowy DR, Schiller JT, (2004) Efficient intracellular assembly of papillomaviral vectors. J Virol 78: 751-757.
38. Buck CB, Pastrana DV, Lowy DR, Schiller JT, (2005) Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 119: 445-462.
39. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, et al. (2009) Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 83: 2067-2074.
40. Karanam B, Jagu S, Huh WK, Roden RB, (2009) Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol 87: 287-299.